{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:06:29Z","timestamp":1791821189355,"version":"4.3.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,15]]},"DOI":"10.7759\/cureus.99275","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:55:31Z","timestamp":1765806931000},"source":"Crossref","is-referenced-by-count":1,"title":["Emerging Therapeutic Synergies: Combining PD-1 Inhibitors With Poly-ADP-Ribose Polymerase (PARP) Inhibitors in the Treatment of Gynecologic Cancers"],"prefix":"10.7759","author":[{"given":"Mohamed Sheeraz","family":"Mohamed Azhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Loh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis T","family":"Mutamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Algahiny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafiu Mukhtar","family":"Yunusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharwini","family":"Paramasevon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manar","family":"Almusarhed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel RL","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023, 73:17-48. 10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: an overview","author":"Ferlay J","year":"2021","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pi\u00f1eros M, Znaor A, Bray F. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021, 10.1002\/ijc.33588","journal-title":"Int J Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Ledermann JA","year":"2013","unstructured":"Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013, 24:24-32. 10.1093\/annonc\/mdt333","journal-title":"Ann Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21559","article-title":"Epithelial ovarian cancer: evolution of management in the era of precision medicine","volume":"69","author":"Lheureux S","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019, 69:280-304. 10.3322\/caac.21559","journal-title":"CA Cancer J Clin"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-018-1018-z","article-title":"Hysterectomy-corrected rates of endometrial cancer among women younger than age 50 in the United States","volume":"29","author":"Temkin SM","year":"2018","unstructured":"Temkin SM, Kohn EC, Penberthy L, et al.. Hysterectomy-corrected rates of endometrial cancer among women younger than age 50 in the United States. Cancer Causes Control. 2018, 29:427-33. 10.1007\/s10552-018-1018-z","journal-title":"Cancer Causes Control"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000005321","article-title":"Trends in uterine cancer mortality in the United States: a 50-year population-based analysis","volume":"142","author":"Somasegar S","year":"2023","unstructured":"Somasegar S, Bashi A, Lang SM, et al.. Trends in uterine cancer mortality in the United States: a 50-year population-based analysis. Obstet Gynecol. 2023, 142:978-86. 10.1097\/AOG.0000000000005321","journal-title":"Obstet Gynecol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00324-8","article-title":"Endometrial cancer","volume":"7","author":"Makker V","year":"2021","unstructured":"Makker V, MacKay H, Ray-Coquard I, Levine DA, Westin SN, Aoki D, Oaknin A. Endometrial cancer. Nat Rev Dis Primers. 2021, 7:10.1038\/s41572-021-00324-8","journal-title":"Nat Rev Dis Primers"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2020.06.05","article-title":"Cervical cancer: epidemiology, risk factors and screening","volume":"32","author":"Zhang S","year":"2020","unstructured":"Zhang S, Xu H, Zhang L, Qiao Y. Cervical cancer: epidemiology, risk factors and screening. Chin J Cancer Res. 2020, 32:720-8. 10.21147\/j.issn.1000-9604.2020.06.05","journal-title":"Chin J Cancer Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman AD","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020, 20:651-68. 10.1038\/s41577-020-0306-5","journal-title":"Nat Rev Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2014.04.010","article-title":"Programmed death-1 pathway in cancer and autoimmunity","volume":"153","author":"Pedoeem A","year":"2014","unstructured":"Pedoeem A, Azoulay-Alfaguter I, Strazza M, Silverman GJ, Mor A. Programmed death-1 pathway in cancer and autoimmunity. Clin Immunol. 2014, 153:145-52. 10.1016\/j.clim.2014.04.010","journal-title":"Clin Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander RN","year":"2023","unstructured":"Eskander RN, Sill MW, Beffa L, et al.. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med. 2023, 388:2159-70. 10.1056\/NEJMoa2302312","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle A","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, et al.. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020, 38:1-10. 10.1200\/JCO.19.02105","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5732\/cjc.011.10111","article-title":"PARP inhibitors: its role in treatment of cancer","volume":"30","author":"Chen A","year":"2011","unstructured":"Chen A. PARP inhibitors: its role in treatment of cancer. Chin J Cancer. 2011, 30:463-71. 10.5732\/cjc.011.10111","journal-title":"Chin J Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31307","article-title":"PARP inhibitors in breast cancer: bringing synthetic lethality to the bedside","volume":"124","author":"Turk AA","year":"2018","unstructured":"Turk AA, Wisinski KB. PARP inhibitors in breast cancer: bringing synthetic lethality to the bedside. Cancer. 2018, 124:2498-506. 10.1002\/cncr.31307","journal-title":"Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos PA","year":"2015","unstructured":"Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D'Andrea AD. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 2015, 5:1137-54. 10.1158\/2159-8290.CD-15-0714","journal-title":"Cancer Discov"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore K","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, et al.. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018, 379:2495-505. 10.1056\/NEJMoa1810858","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza MR","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, et al.. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016, 375:2154-64. 10.1056\/NEJMoa1611310","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn A","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, et al.. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019, 381:2391-402. 10.1056\/NEJMoa1910962","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro P","year":"2023","unstructured":"DiSilvestro P, Banerjee S, Colombo N, et al.. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial. J Clin Oncol. 2023, 41:609-17. 10.1200\/JCO.22.01549","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1218","article-title":"PARP inhibitor efficacy depends on CD8+ T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer","volume":"9","author":"Pantelidou C","year":"2019","unstructured":"Pantelidou C, Sonzogni O, Taveira M, et al.. PARP inhibitor efficacy depends on CD8+ T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov. 2019, 9:722-37. 10.1158\/2159-8290.CD-18-1218","journal-title":"Cancer Discov"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2022.12.031","article-title":"Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control","volume":"83","author":"Concannon K","year":"2023","unstructured":"Concannon K, Morris BB, Gay CM, Byers LA. Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control. Mol Cell. 2023, 83:660-80. 10.1016\/j.molcel.2022.12.031","journal-title":"Mol Cell"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib","volume":"13","author":"Murai J","year":"2014","unstructured":"Murai J, Huang SY, Renaud A, et al.. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther. 2014, 13:433-43. 10.1158\/1535-7163.MCT-13-0803","journal-title":"Mol Cancer Ther"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2021.10367","article-title":"Combination treatment with cisplatin, paclitaxel and olaparib has synergistic and dose reduction potential in ovarian cancer cells","volume":"22","author":"Gao J","year":"2021","unstructured":"Gao J, Wang Z, Fu J, Jisaihan A, Ohno Y, Xu C. Combination treatment with cisplatin, paclitaxel and olaparib has synergistic and dose reduction potential in ovarian cancer cells. Exp Ther Med. 2021, 22:10.3892\/etm.2021.10367","journal-title":"Exp Ther Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15315-8","article-title":"Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer","volume":"11","author":"F\u00e4rkkil\u00e4 A","year":"2020","unstructured":"F\u00e4rkkil\u00e4 A, Gulhan DC, Casado J, et al.. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun. 2020, 11:10.1038\/s41467-020-15315-8","journal-title":"Nat Commun"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-1003","article-title":"PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness","volume":"79","author":"Shen J","year":"2019","unstructured":"Shen J, Zhao W, Ju Z, et al.. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res. 2019, 79:311-9. 10.1158\/0008-5472.CAN-18-1003","journal-title":"Cancer Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.11.054","article-title":"PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer","volume":"25","author":"Ding L","year":"2018","unstructured":"Ding L, Kim HJ, Wang Q, et al.. PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer. Cell Rep. 2018, 25:2972-80. 10.1016\/j.celrep.2018.11.054","journal-title":"Cell Rep"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1172\/JCI123319","article-title":"PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer","volume":"129","author":"Chabanon RM","year":"2019","unstructured":"Chabanon RM, Muirhead G, Krastev DB, et al.. PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer. J Clin Invest. 2019, 129:1211-28. 10.1172\/JCI123319","journal-title":"J Clin Invest"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP Inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression","volume":"23","author":"Jiao S","year":"2017","unstructured":"Jiao S, Xia W, Yamaguchi H, et al.. PARP Inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res. 2017, 23:3711-20. 10.1158\/1078-0432.CCR-16-3215","journal-title":"Clin Cancer Res"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-38534-6","article-title":"Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models","volume":"9","author":"Wang Z","year":"2019","unstructured":"Wang Z, Sun K, Xiao Y, et al.. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models. Sci Rep. 2019, 9:10.1038\/s41598-019-38534-6","journal-title":"Sci Rep"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100536","article-title":"Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?","volume":"7","author":"Musacchio L","year":"2022","unstructured":"Musacchio L, Cicala CM, Camarda F, et al.. Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?. ESMO Open. 2022, 7:10.1016\/j.esmoop.2022.100536","journal-title":"ESMO Open"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1177\/1179554921996288","article-title":"The synergistic effect of PARP inhibitors and immune checkpoint inhibitors","volume":"15","author":"Wu Z","year":"2021","unstructured":"Wu Z, Cui P, Tao H, et al.. The synergistic effect of PARP inhibitors and immune checkpoint inhibitors. Clin Med Insights Oncol. 2021, 15:10.1177\/1179554921996288","journal-title":"Clin Med Insights Oncol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2024.102697","article-title":"The challenge of ovarian cancer care in the oldest old","volume":"95","author":"Barben J","year":"2025","unstructured":"Barben J, Galvin A, Kamga AM, et al.. The challenge of ovarian cancer care in the oldest old. Cancer Epidemiol. 2025, 95:10.1016\/j.canep.2024.102697","journal-title":"Cancer Epidemiol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34350","article-title":"Real-life data on treatment and outcomes in advanced ovarian cancer: an observational, multinational cohort study (RESPONSE trial)","volume":"128","author":"Marth C","year":"2022","unstructured":"Marth C, Abreu MH, Andersen KK, et al.. Real-life data on treatment and outcomes in advanced ovarian cancer: an observational, multinational cohort study (RESPONSE trial). Cancer. 2022, 128:3080-9. 10.1002\/cncr.34350","journal-title":"Cancer"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012067","article-title":"Focus on PD-1\/PD-L1 as a therapeutic target in ovarian cancer","volume":"23","author":"Dumitru A","year":"2022","unstructured":"Dumitru A, Dobrica EC, Croitoru A, Cretoiu SM, Gaspar BS. Focus on PD-1\/PD-L1 as a therapeutic target in ovarian cancer. Int J Mol Sci. 2022, 23:10.3390\/ijms232012067","journal-title":"Int J Mol Sci"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma","volume":"5","author":"Konstantinopoulos PA","year":"2019","unstructured":"Konstantinopoulos PA, Waggoner S, Vidal GA, et al.. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol. 2019, 5:1141-9. 10.1001\/jamaoncol.2019.1048","journal-title":"JAMA Oncol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2269","article-title":"LBA30 ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC)","volume":"35","author":"Monk BJ","year":"2024","unstructured":"Monk BJ, Mikheeva O, Oaknin A, et al.. LBA30 ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC). Ann Oncol. 2024, 35:1223-4. 10.1016\/j.annonc.2024.08.2269","journal-title":"Ann Oncol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0056","article-title":"Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study","volume":"26","author":"Lampert EJ","year":"2020","unstructured":"Lampert EJ, Zimmer A, Padget M, et al.. Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study. Clin Cancer Res. 2020, 26:4268-79. 10.1158\/1078-0432.CCR-20-0056","journal-title":"Clin Cancer Res"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-2249","article-title":"Olaparib plus durvalumab, with or without bevacizumab, as treatment in PARP inhibitor-na\u00efve platinum-sensitive relapsed ovarian cancer: a phase II multi-cohort study","volume":"30","author":"Drew Y","year":"2024","unstructured":"Drew Y, Kim JW, Penson RT, et al.. Olaparib plus durvalumab, with or without bevacizumab, as treatment in PARP inhibitor-na\u00efve platinum-sensitive relapsed ovarian cancer: a phase II multi-cohort study. Clin Cancer Res. 2024, 30:50-62. 10.1158\/1078-0432.CCR-23-2249","journal-title":"Clin Cancer Res"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.2181","article-title":"Evaluation of treatment with talazoparib and avelumab in patients with recurrent mismatch repair proficient endometrial cancer","volume":"8","author":"Konstantinopoulos PA","year":"2022","unstructured":"Konstantinopoulos PA, Gockley AA, Xiong N, et al.. Evaluation of treatment with talazoparib and avelumab in patients with recurrent mismatch repair proficient endometrial cancer. JAMA Oncol. 2022, 8:1317-22. 10.1001\/jamaoncol.2022.2181","journal-title":"JAMA Oncol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.02.025","article-title":"Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial)","volume":"165","author":"Post CC","year":"2022","unstructured":"Post CC, Westermann AM, Boere IA, et al.. Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial). Gynecol Oncol. 2022, 165:223-9. 10.1016\/j.ygyno.2022.02.025","journal-title":"Gynecol Oncol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45974-w","article-title":"Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group","volume":"15","author":"Freyer G","year":"2024","unstructured":"Freyer G, Floquet A, Tredan O, et al.. Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nat Commun. 2024, 15:10.1038\/s41467-024-45974-w","journal-title":"Nat Commun"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40829-2","article-title":"Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01\/APGOT-OV4","volume":"14","author":"Kim YN","year":"2023","unstructured":"Kim YN, Park B, Kim JW, et al.. Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01\/APGOT-OV4. Nat Commun. 2023, 14:10.1038\/s41467-023-40829-2","journal-title":"Nat Commun"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00693","article-title":"Niraparib, dostarlimab, and bevacizumab as combination therapy in pretreated, advanced platinum-resistant ovarian cancer: findings from cohort A of the OPAL phase II trial","volume":"8","author":"Liu JF","year":"2024","unstructured":"Liu JF, Gaillard S, Hendrickson AE, et al.. Niraparib, dostarlimab, and bevacizumab as combination therapy in pretreated, advanced platinum-resistant ovarian cancer: findings from cohort A of the OPAL phase II trial. JCO Precis Oncol. 2024, 8:10.1200\/PO.23.00693","journal-title":"JCO Precis Oncol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-14-0654","article-title":"Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type","volume":"23","author":"Gatalica Z","year":"2014","unstructured":"Gatalica Z, Snyder C, Maney T, et al.. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev. 2014, 23:2965-70. 10.1158\/1055-9965.EPI-14-0654","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial","volume":"42","author":"Westin SN","year":"2024","unstructured":"Westin SN, Moore K, Chon HS, et al.. Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial. J Clin Oncol. 2024, 42:283-99. 10.1200\/JCO.23.02132","journal-title":"J Clin Oncol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.05.009","article-title":"Dostarlimab and niraparib in primary advanced ovarian cancer","volume":"36","author":"Hardy-Bessard AC","year":"2025","unstructured":"Hardy-Bessard AC, Pujade-Lauraine E, Moore RG, et al.. Dostarlimab and niraparib in primary advanced ovarian cancer. Ann Oncol. 2025, 36:1503-13. 10.1016\/j.annonc.2025.05.009","journal-title":"Ann Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/446292-emerging-therapeutic-synergies-combining-pd-1-inhibitors-with-poly-adp-ribose-polymerase-parp-inhibitors-in-the-treatment-of-gynecologic-cancers","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:55:32Z","timestamp":1765806932000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/446292-emerging-therapeutic-synergies-combining-pd-1-inhibitors-with-poly-adp-ribose-polymerase-parp-inhibitors-in-the-treatment-of-gynecologic-cancers"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":47,"URL":"https:\/\/doi.org\/10.7759\/cureus.99275","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,15]]}}}